Title:
COMPOSITION FOR USE IN TREATMENT OF CANCER, INFLAMMATORY DISEASES, OR OBESITY, AND USE THEREOF
Document Type and Number:
WIPO Patent Application WO/2023/157891
Kind Code:
A1
Abstract:
The present invention addresses the problem of providing a drug for use in the treatment of triple-negative breast cancer, providing a blood marker for triple-negative breast cancer, and providing a drug for use in the treatment of inflammatory diseases or obesity. A medicinal composition for use in the treatment of triple-negative breast cancer, inflammatory diseases, or obesity can be produced by employing, as an active ingredient, an inhibitor of the ZCCHC24 protein or a drug for inhibiting the expression of the ZCCHC24 gene. The inhibitor of the ZCCHC24 protein or a drug for inhibiting the expression of the ZCCHC24 gene can be used in combination with a BET inhibitor.
Inventors:
ASAHARA HIROSHI (JP)
UCHIDA YUTARO (JP)
KURIMOTO RYOTA (JP)
CHIBA TOMOKI (JP)
UCHIDA YUTARO (JP)
KURIMOTO RYOTA (JP)
CHIBA TOMOKI (JP)
Application Number:
PCT/JP2023/005320
Publication Date:
August 24, 2023
Filing Date:
February 15, 2023
Export Citation:
Assignee:
UNIV NAT CORP TOKYO MEDICAL & DENTAL (JP)
International Classes:
A61K31/437; A61K45/00; A61K31/4433; A61K31/519; A61K31/52; A61K31/551; A61K31/7088; A61K31/7105; A61K39/395; A61K45/06; A61P15/00; A61P29/00; A61P35/00; A61P43/00; C07D405/04; C07D471/04; C07D473/16; C07D487/04; C07D495/14; C07K16/18; C12N15/09; C12N15/11; G01N33/15; G01N33/50; G01N33/68
Foreign References:
| JP2018531891A | 2018-11-01 |
Other References:
ALI REEM, ALBLIHY ADEL, TOSS MICHAEL S., ALGETHAMI MASHAEL, AL SUNNI RABAB, GREEN ANDREW R., RAKHA EMAD A., MADHUSUDAN SRINIVASAN: "XRCC1 deficient triple negative breast cancers are sensitive to ATR, ATM and Wee1 inhibitor either alone or in combination with olaparib", THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, SAGE PUBLISHING, vol. 12, 1 January 2020 (2020-01-01), pages 175883592097420, XP093086682, ISSN: 1758-8359, DOI: 10.1177/1758835920974201
GRUENER ROBERT F., LING ALEXANDER, CHANG YA-FANG, MORRISON GLADYS, GEELEHER PAUL, GREENE GEOFFREY L., HUANG R. STEPHANIE: "Facilitating Drug Discovery in Breast Cancer by Virtually Screening Patients Using In Vitro Drug Response Modeling", CANCERS, vol. 13, no. 4, 20 February 2021 (2021-02-20), pages 885, XP093086684, DOI: 10.3390/cancers13040885
CHEN XIAN, YANG DONG, CAREY JASON P. W., KARAKAS CANSU, ALBARRACIN CONSTANCE, SAHIN AYSEGUL A., ARUN BANU K., GURAY DURAK MERIH, L: "Targeting Replicative Stress and DNA Repair by Combining PARP and Wee1 Kinase Inhibitors Is Synergistic in Triple Negative Breast Cancers with Cyclin E or BRCA1 Alteration", CANCERS, M D P I AG, CH, vol. 13, no. 7, 1 April 2021 (2021-04-01), CH , pages 1656, XP093020957, ISSN: 2072-6694, DOI: 10.3390/cancers13071656
GLINKA YELENA, MOHAMMED NADA, SUBRAMANIAM VENKATESWARAN, JOTHY SERGE, PRUD’HOMME GÉRALD J.: "Neuropilin-1 is expressed by breast cancer stem-like cells and is linked to NF-κB activation and tumor sphere formation", BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, ELSEVIER, AMSTERDAM NL, vol. 425, no. 4, 1 September 2012 (2012-09-01), Amsterdam NL , pages 775 - 780, XP093086688, ISSN: 0006-291X, DOI: 10.1016/j.bbrc.2012.07.151
YU-CHIAO CHIU;LI-JU WANG;TZU-HUNG HSIAO;ERICY. CHUANG;YIDONG CHEN: "Genome-wide identification of key modulators of gene-gene interaction networks in breast cancer", BMC GENOMICS, BIOMED CENTRAL LTD, LONDON, UK, vol. 18, no. 6, 3 October 2017 (2017-10-03), London, UK , pages 119 - 130, XP021249672, DOI: 10.1186/s12864-017-4028-4
LIN XIAOYU, HUANG XIAOLI, UZIEL TAMAR, HESSLER PAUL, ALBERT DANIEL H., ROBERTS-RAPP LISA A., MCDANIEL KEITH F., KATI WARREN M., SH: "HEXIM1 as a Robust Pharmacodynamic Marker for Monitoring Target Engagement of BET Family Bromodomain Inhibitors in Tumors and Surrogate Tissues", MOLECULAR CANCER THERAPEUTICS, AMERICAN ASSOCIATION FOR CANCER RESEARCH, US, vol. 16, no. 2, 1 February 2017 (2017-02-01), US , pages 388 - 396, XP055885151, ISSN: 1535-7163, DOI: 10.1158/1535-7163.MCT-16-0475
MCLAUGHLIN RONAN P., HE JICHAO, VAN DER NOORD VERA E., REDEL JEVIN, FOEKENS JOHN A., MARTENS JOHN W. M., SMID MARCEL, ZHANG YINGHU: "A kinase inhibitor screen identifies a dual cdc7/CDK9 inhibitor to sensitise triple-negative breast cancer to EGFR-targeted therapy", BREAST CANCER RESEARCH, vol. 21, no. 1, 1 December 2019 (2019-12-01), pages 77, XP093086691, DOI: 10.1186/s13058-019-1161-9
GRUENER ROBERT F., LING ALEXANDER, CHANG YA-FANG, MORRISON GLADYS, GEELEHER PAUL, GREENE GEOFFREY L., HUANG R. STEPHANIE: "Facilitating Drug Discovery in Breast Cancer by Virtually Screening Patients Using In Vitro Drug Response Modeling", CANCERS, vol. 13, no. 4, 20 February 2021 (2021-02-20), pages 885, XP093086684, DOI: 10.3390/cancers13040885
CHEN XIAN, YANG DONG, CAREY JASON P. W., KARAKAS CANSU, ALBARRACIN CONSTANCE, SAHIN AYSEGUL A., ARUN BANU K., GURAY DURAK MERIH, L: "Targeting Replicative Stress and DNA Repair by Combining PARP and Wee1 Kinase Inhibitors Is Synergistic in Triple Negative Breast Cancers with Cyclin E or BRCA1 Alteration", CANCERS, M D P I AG, CH, vol. 13, no. 7, 1 April 2021 (2021-04-01), CH , pages 1656, XP093020957, ISSN: 2072-6694, DOI: 10.3390/cancers13071656
GLINKA YELENA, MOHAMMED NADA, SUBRAMANIAM VENKATESWARAN, JOTHY SERGE, PRUD’HOMME GÉRALD J.: "Neuropilin-1 is expressed by breast cancer stem-like cells and is linked to NF-κB activation and tumor sphere formation", BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, ELSEVIER, AMSTERDAM NL, vol. 425, no. 4, 1 September 2012 (2012-09-01), Amsterdam NL , pages 775 - 780, XP093086688, ISSN: 0006-291X, DOI: 10.1016/j.bbrc.2012.07.151
YU-CHIAO CHIU;LI-JU WANG;TZU-HUNG HSIAO;ERICY. CHUANG;YIDONG CHEN: "Genome-wide identification of key modulators of gene-gene interaction networks in breast cancer", BMC GENOMICS, BIOMED CENTRAL LTD, LONDON, UK, vol. 18, no. 6, 3 October 2017 (2017-10-03), London, UK , pages 119 - 130, XP021249672, DOI: 10.1186/s12864-017-4028-4
LIN XIAOYU, HUANG XIAOLI, UZIEL TAMAR, HESSLER PAUL, ALBERT DANIEL H., ROBERTS-RAPP LISA A., MCDANIEL KEITH F., KATI WARREN M., SH: "HEXIM1 as a Robust Pharmacodynamic Marker for Monitoring Target Engagement of BET Family Bromodomain Inhibitors in Tumors and Surrogate Tissues", MOLECULAR CANCER THERAPEUTICS, AMERICAN ASSOCIATION FOR CANCER RESEARCH, US, vol. 16, no. 2, 1 February 2017 (2017-02-01), US , pages 388 - 396, XP055885151, ISSN: 1535-7163, DOI: 10.1158/1535-7163.MCT-16-0475
MCLAUGHLIN RONAN P., HE JICHAO, VAN DER NOORD VERA E., REDEL JEVIN, FOEKENS JOHN A., MARTENS JOHN W. M., SMID MARCEL, ZHANG YINGHU: "A kinase inhibitor screen identifies a dual cdc7/CDK9 inhibitor to sensitise triple-negative breast cancer to EGFR-targeted therapy", BREAST CANCER RESEARCH, vol. 21, no. 1, 1 December 2019 (2019-12-01), pages 77, XP093086691, DOI: 10.1186/s13058-019-1161-9
Attorney, Agent or Firm:
WATANABE Shinichi (JP)
Download PDF: